Evgen Pharma PLC (AIM:EVG) (Evgen Pharma PLC (AIM:EVG)) Huw Jones joins Proactive London to talk about making headways towards clinical trials in 2022 and regulators on both sides of the Atlantic.
The firm has also met with the Medicines and Healthcare products Regulatory Agency (MHRA) to discuss protocols for a phase I study of the new tablet form of SFX-01, its lead asset.
In the US, the company will submit a ‘package’ of information ahead of a meeting with the Food & Drug Administration.